recovery in the domestic business front but registered a 27% YoY degrowth due to a higher base in Q1FY21 attributable to covid sales. The company reported strong growth in domestic business with a strong position in oncology and hepatitis-c domains. APIs registered a decline of 57% YoY and export formulations de-grew 47% YoY to 145cr. Resultantly, EBITDA margins contracted 300bps YoY to 27% and EBITDA declined 35.8% YoY to Rs.109.8cr. With approval in both Hyderabad and Vizag facilities, Revlimid is expected to be launched in the March quarter of FY22. In the agro-chemical business front, the company has launched...